Free Trial
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Cellectar Biosciences logo
$0.32 0.00 (-0.91%)
Closing price 03/10/2025 04:00 PM Eastern
Extended Trading
$0.31 -0.01 (-1.94%)
As of 03/10/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Key Stats

Today's Range
$0.31
$0.34
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$4.17
Volume
1.29 million shs
Average Volume
1.69 million shs
Market Capitalization
$14.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67
Consensus Rating
Moderate Buy

Company Overview

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Remove Ads

Cellectar Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

CLRB MarketRank™: 

Cellectar Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 596th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cellectar Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.59) to ($0.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cellectar Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cellectar Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cellectar Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    5.17% of the float of Cellectar Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectar Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectar Biosciences has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cellectar Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cellectar Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.17% of the float of Cellectar Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectar Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectar Biosciences has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Cellectar Biosciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    12 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.70% of the stock of Cellectar Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 16.41% of the stock of Cellectar Biosciences is held by institutions.

  • Read more about Cellectar Biosciences' insider trading history.
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Stock News Headlines

The real reason gold is soaring (and likely to continue)
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!
See More Headlines

CLRB Stock Analysis - Frequently Asked Questions

Cellectar Biosciences' stock was trading at $0.2990 at the beginning of the year. Since then, CLRB stock has increased by 5.4% and is now trading at $0.3151.
View the best growth stocks for 2025 here
.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10.

Shares of Cellectar Biosciences reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences' top institutional shareholders include ADAR1 Capital Management LLC (1.27%), Squarepoint Ops LLC (1.13%), Bank of America Corp DE (0.45%) and JPMorgan Chase & Co. (0.40%).
View institutional ownership trends
.

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Hudbay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
11/07/2021
Today
3/11/2025
Next Earnings (Estimated)
3/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLRB
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.67
High Stock Price Target
$28.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+5,506.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.96) per share
Price / Book
-0.33

Miscellaneous

Free Float
44,375,000
Market Cap
$14.52 million
Optionable
Optionable
Beta
0.96
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:CLRB) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners